Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ: IRON )

32.53 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2023
 
Via Benzinga
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
From Disc Medicine Inc
Via GlobeNewswire
Expert Ratings for Disc Medicine
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
 
Via Benzinga
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
 
Via Benzinga
Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
 
Via Benzinga
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
Why Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
 
Via Benzinga
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023 
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Opco Inc (NASDAQ: IRON) Investor Notice: Investigation over Possible Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/20/2023 -- An investigation was announced for investors of Disc Medicine Opco Inc (NASDAQ: IRON) shares over potential securities laws violations in connection with... 
Via SBWire
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
 
Via Benzinga
$2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
From Disc Medicine Inc
Via GlobeNewswire
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in... 
Via Talk Markets
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
From Disc Medicine Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
 
Via Benzinga
Stocks Stumbling Out Of 2023's Gate
Stocks were unable to fulfill premarket gains, as two familiar foes -- rising rates and high inflation -- dampen investor sentiment to start the new trading year. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.